Analysis of the Phase II, Phase IIB, and Phase V SOCs for the
purposes of determining compliance with the MCL must be conducted as
follows:
a) Definitions. As used in
this Section, the following terms will have the following meanings:
"Detect" or "detection" means that the contaminant of
interest is present at a level greater than or equal to the "detection
limit".
"Detection limit" means the level of the contaminant of
interest that is specified in subsection (r).
BOARD NOTE: This is a "trigger level" for Phase II, Phase
IIB, and Phase V SOCs inasmuch as it prompts further action. The use of the
term "detect" or "detection" in this Section is not intended to include any
analytical capability of quantifying lower levels of any contaminant, or the
"method detection limit".
b) Required Sampling. Each supplier must take
a minimum of one sample at each sampling point at the times required in
subsection (q).
BOARD NOTE: See the Board note appended to Section
611.311(c) for
information relating to implementation of requirements relating to aldicarb,
aldicarb sulfone, and aldicarb sulfoxide.
c) Sampling Points
1) Sampling Points for GWSs. Unless otherwise
provided in a SEP, a GWS supplier must take at least one sample from each of
the following points: each entry point that is representative of each well
after treatment.
2) Sampling Points
for an SWS or Mixed System Supplier. Unless otherwise provided in a SEP, an SWS
or mixed system supplier must sample from each of the following points:
A) Each entry point after treatment;
or
B) Points in the distribution
system that are representative of each source.
3) The supplier must take each sample at the
same sampling point unless the Agency issues a SEP that designates another
location as more representative of each source, treatment plant, or within the
distribution system.
4) If a system
draws water from more than one source, and the sources are combined before
distribution, the supplier must sample at an entry point during periods of
normal operating conditions when water is representative of all sources being
used.
BOARD NOTE: Subsections (b) and (c) derive from
40 CFR
141.24(h)(1) through
(h)(3).
d) Monitoring Frequency
1) Each CWS and NTNCWS supplier must take
four consecutive quarterly samples for each of the Phase II, Phase IIB, and
Phase V SOCs during each compliance period, beginning in the three-year
compliance period starting in the initial compliance period.
2) Suppliers serving more than 3,300 persons
that do not detect a contaminant in the initial compliance period must take a
minimum of two quarterly samples in one year of each subsequent three-year
compliance period.
3) Suppliers
serving fewer than or equal to 3,300 persons that do not detect a contaminant
in the initial compliance period must take a minimum of one sample during each
subsequent three-year compliance period.
e) Reduction to Annual Monitoring Frequency.
A CWS or NTNCWS supplier may apply to the Agency for a SEP releasing the
supplier from the requirements of subsection (d). A SEP from the requirement of
subsection (d) may last for only a single three-year compliance
period.
f) Vulnerability
Assessment. The Agency must issue a SEP from the requirements of subsection (d)
based on consideration of the factors set forth at Section
611.110(a).
g) If one of the Phase II, Phase IIB, or
Phase V SOCs is detected in any sample, then the following must occur:
1) The supplier must monitor quarterly for
the contaminant at each sampling point that resulted in a detection.
2) Annual Monitoring
A) A supplier may request that the Agency
issue a SEP reducing the monitoring frequency to annual.
B) A request for a SEP must include the
following minimal information:
i) For a GWS,
two quarterly samples.
ii) For an
SWS or mixed system supplier, four quarterly samples.
C) The Agency must issue a SEP allowing
annual monitoring at a sampling point if it determines that the sampling point
is reliably and consistently below the MCL.
D) When issuing the SEP, the Agency must
specify the level of the contaminant upon which the "reliably and consistently
below the MCL" determination was based. Any SEP allowing less frequent
monitoring based on an Agency "reliably and consistently below the MCL"
determination must include a condition requiring the supplier to resume
quarterly monitoring under subsection (g)(1) if it detects any Phase II
SOC.
3) Suppliers that
monitor annually must monitor during the quarters that previously yielded the
highest analytical result.
4)
Suppliers that have three consecutive annual samples with no detection of a
contaminant at a sampling point may apply to the Agency for a SEP with respect
to that point, as specified in subsections (e) and (f).
5) Monitoring for Related Contaminants
A) If monitoring results in detection of one
or more of the related contaminants listed in subsection (g)(5)(B), subsequent
monitoring must analyze for all the related compounds in the respective
group.
B) Related Contaminants
i) First Group
aldicarb
aldicarb sulfone
aldicarb sulfoxide
BOARD NOTE: See the Board note appended to Section
611.311(c) for
information relating to implementation of requirements relating to aldicarb,
aldicarb sulfone, and aldicarb sulfoxide.
ii) Second Group
heptachlor
heptachlor epoxide.
h) Quarterly Monitoring Following
MCL Violations
1) Suppliers that violate an
MCL for one of the Phase II, Phase IIB, or Phase V SOCs, as determined by
subsection (k), must monitor quarterly for that contaminant at the sampling
point where the violation occurred, beginning the next quarter after the
violation.
2) Annual Monitoring
A) A supplier may request that the Agency
issue a SEP reducing the monitoring frequency to annual.
B) A request for a SEP must include, at a
minimum, the results from four quarterly samples.
C) The Agency must issue a SEP allowing
annual monitoring at a sampling point if it determines that the sampling point
is reliably and consistently below the MCL.
D) When issuing the SEP, the Agency must
specify the level of the contaminant upon which the "reliably and consistently
below the MCL" determination was based. Any SEP allowing less frequent
monitoring based on an Agency "reliably and consistently below the MCL"
determination must include a condition requiring the supplier to resume
quarterly monitoring under subsection (h)(1) if it detects any Phase II
SOC.
E) The supplier must monitor
during the quarters that previously yielded the highest analytical
result.
i)
Confirmation Samples
1) If any of the Phase
II, Phase IIB, or Phase V SOCs are detected in a sample, the supplier must take
a confirmation sample as soon as possible, but no later than 14 days after the
supplier receives notice of the detection.
2) Averaging is as specified in subsection
(k).
3) The Agency must delete the
original or confirmation sample if it determines that a sampling error
occurred, in which case the confirmation sample will replace the original or
confirmation sample.
j)
This subsection (j) corresponds with
40 CFR
141.24(h)(10), an optional
USEPA provision relating to compositing of samples that USEPA does not require
for state programs. This statement maintains structural consistency with USEPA
rules.
k) Compliance with the MCLs
for the Phase II, Phase IIB, and Phase V SOCs must be determined based on the
analytical results obtained at each sampling point. If one sampling point is in
violation of an MCL, the supplier is in violation of the MCL.
1) For a supplier that monitors more than
once per year, compliance with the MCL is determined by a running annual
average at each sampling point.
2)
A supplier that monitors annually or less frequently whose sample result
exceeds the regulatory detection level as defined by subsection (r) must begin
quarterly sampling. The system will not be considered in violation of the MCL
until it has completed one year of quarterly sampling.
3) If any sample result will cause the
running annual average to exceed the MCL at any sampling point, the supplier is
out of compliance with the MCL immediately.
4) If a supplier fails to collect the
required number of samples, compliance will be based on the total number of
samples collected.
5) If a sample
result is less than the detection limit, zero will be used to calculate the
annual average.
l) This
subsection (l) corresponds with
40 CFR
141.24(h)(12), which USEPA
removed and reserved. This statement maintains structural consistency with the
federal regulations.
m) Analysis
for PCBs must be conducted as follows using the methods in Section
611.645:
1) Each supplier that monitors for PCBs must
analyze each sample using either USEPA 505 (95) or USEPA 508 (95).
2) If PCBs are detected in any sample
analyzed using USEPA 505 (95) or USEPA 508 (95), the supplier must reanalyze
the sample using USEPA 508A (89) to quantitate the individual Aroclors (as
decachlorobiphenyl).
3) Compliance
with the PCB MCL must be determined based upon the quantitative results of
analyses using USEPA 508A (89).
n) This subsection (n) corresponds with
40 CFR
141.24(h)(14), an obsolete
provision that relates to the initial compliance period from 1993 through 1995.
This statement maintains consistency with the federal regulations.
o) The Agency must issue a SEP increasing the
number of sampling points or the frequency of monitoring if it determines that
this is necessary to detect variations within the PWS due to such factors as
fluctuations in contaminant concentration due to seasonal use or changes in the
water source.
BOARD NOTE: At
40 CFR
141.24(h)(15), the factors
are non-limiting examples of circumstances making additional monitoring
necessary.
p) This
subsection (p) corresponds with
40 CFR
141.24(h)(16), a USEPA
provision relating to reserving enforcement authority to the State that would
serve no useful function as part of the State's rules. This statement maintains
structural consistency with USEPA rules.
q) Each supplier must monitor, within each
compliance period, at the time designated by the Agency in a SEP.
r) "Detection" means greater than or equal to
the following concentrations for each contaminant:
1) For PCBs (Aroclors), the following:
2)
For other Phase II, Phase IIB, and Phase V SOCs, the following:
Contaminant
|
Detection Limit (mg/L)
|
Alachlor
|
0.0002
|
Aldicarb
|
0.0005
|
Aldicarb sulfoxide
|
0.0005
|
Aldicarb sulfone
|
0.0008
|
Atrazine
|
0.0001
|
Benzo(a)pyrene
|
0.00002
|
Carbofuran
|
0.0009
|
Chlordane
|
0.0002
|
2,4-D
|
0.0001
|
Dalapon
|
0.001
|
1,2-Dibromo-3-chloropropane (DBCP)
|
0.00002
|
Di(2-ethylhexyl)adipate
|
0.0006
|
Di(2-ethylhexyl)phthalate
|
0.0006
|
Dinoseb
|
0.0002
|
Diquat
|
0.0004
|
Endothall
|
0.009
|
Endrin
|
0.00001
|
Ethylene dibromide (EDB)
|
0.00001
|
Glyphosate
|
0.006
|
Heptachlor
|
0.00004
|
Heptachlor epoxide
|
0.00002
|
Hexachlorobenzene
|
0.0001
|
Hexachlorocyclopentadiene
|
0.0001
|
Lindane
|
0.00002
|
Methoxychlor
|
0.0001
|
Oxamyl
|
0.002
|
Picloram
|
0.0001
|
Polychlorinated biphenyls (PCBs) (as
decachlorobiphenyl)
|
0.0001
|
Pentachlorophenol
|
0.00004
|
Simazine
|
0.00007
|
Toxaphene
|
0.001
|
2,3,7,8-TCDD (dioxin)
|
0.000000005
|
2,4,5-TP (silvex)
|
0.0002
|
BOARD NOTE: See the Board note appended to Section
611.311(c) for
information relating to implementation of requirements relating to aldicarb,
aldicarb sulfone, and aldicarb sulfoxide.
s) Laboratory Certification
1) Analyses under this Section must only be
conducted by a laboratory in one of the categories listed in Section
611.490(a)
that has been certified according to the conditions of subsection
(s)(2).
2) To receive certification
to conduct analyses for the Phase II, Phase IIB, and Phase V SOCs, the
laboratory must do the following:
A) Analyze
PE samples provided by the Agency under 35 Ill. Adm. Code
183.125(c) that
include these substances; and
B)
Achieve quantitative results on the analyses performed under subsection
(s)(2)(A) that are within the following acceptance limits:
SOC
|
Acceptance Limits
|
Alachlor
|
± 45%
|
Aldicarb
|
2 standard deviations
|
Aldicarb sulfone
|
2 standard deviations
|
Aldicarb sulfoxide
|
2 standard deviations
|
Atrazine
|
± 45%
|
Benzo(a)pyrene
|
2 standard deviations
|
Carbofuran
|
± 45%
|
Chlordane
|
± 45%
|
Dalapon
|
2 standard deviations
|
Di(2-ethylhexyl)adipate
|
2 standard deviations
|
Di(2-ethylhexyl)phthalate
|
2 standard deviations
|
Dinoseb
|
2 standard deviations
|
Diquat
|
2 standard deviations
|
Endothall
|
2 standard deviations
|
Endrin
|
± 30%
|
Glyphosate
|
2 standard deviations
|
Dibromochloropropane (DBCP)
|
± 40%
|
Ethylene dibromide (EDB)
|
± 40%
|
Heptachlor
|
± 45%
|
Heptachlor epoxide
|
± 45%
|
Hexachlorobenzene
|
2 standard deviations
|
Hexachlorocyclopentadiene
|
2 standard deviations
|
Lindane
|
± 45%
|
Methoxychlor
|
± 45%
|
Oxamyl
|
2 standard deviations
|
PCBs (as decachlorobiphenyl)
|
0-200%
|
Pentachlorophenol
|
± 50%
|
Picloram
|
2 standard deviations
|
Simazine
|
2 standard deviations
|
Toxaphene
|
± 45%
|
2,4-D
|
± 50%
|
2,3,7,8-TCDD (dioxin)
|
2 standard deviations
|
2,4,5-TP (silvex)
|
± 50%
|
BOARD NOTE: See the Board note appended to Section
611.311(c) for
information relating to implementation of requirements relating to aldicarb,
aldicarb sulfone, and aldicarb sulfoxide.
t) A new system supplier or a
supplier using a new source of water must demonstrate compliance with the MCL
within a period of time specified by a permit issued by the Agency. The
supplier must also comply with the initial sampling frequencies specified by
the Agency to ensure the supplier can demonstrate compliance with the MCL.
Routine and increased monitoring frequencies must be conducted in accordance
with the requirements in this Section.